Type 2 diabetes mellitus (T2DM) is the most common type of DM and affects around 95 per cent of people with DM around the world[@ref1][@ref2]. The World Health Organization (WHO) estimated that in 2015, more than 415 million people worldwide were living with diabetes[@ref3], and in 2014, the International Diabetes Federation estimated that diabetes resulted in five million deaths[@ref4].

It is estimated that around 40 to 50 million individuals with diabetes worldwide fast during Ramadan[@ref5]. During fasting, they abstain from eating, drinking, taking oral medications and smoking from sunrise to sunset. Because people fast from dawn to sunset, they consume substantial quantities of sugary foods and carbohydrate-rich meals during non-fasting hours[@ref5]. It is assumed that these traditionally rich foods associated with Ramadan may present a risk of hyperglycaemia and weight gain for diabetic patients[@ref5]. In healthy people, this fasting does not have any harmful consequences on health[@ref6]. However, it can induce several complications in patients with diabetes[@ref7][@ref8]. There is only one previously published meta-analysis that showed the impact of fasting on health parameters in a healthy population[@ref6]. An outcome of interest of other three meta-analysis was the occurrence of hypoglycaemic events in T2DM patients who fast during Ramadan[@ref9][@ref10][@ref11]. There is perhaps no meta-analysis that included before-after studies to show any effect of RF on glycaemic parameters used for monitoring T2DM patients. For this reason, this meta-analysis was conducted including all recent studies on T2DM with the aim to demonstrate the impact of RF on the most widely reported health outcomes including post-prandial plasma glucose (PPG), fasting plasma glucose (FPG), glycated haemoglobin (HbA~1c~) (%), fructosamine levels and body mass index (BMI).

Material & Methods {#sec1-2}
==================

*Literature search*: A systematic review protocol was developed for the meta-analysis, and MEDLINE EBSCO, Google Scholar and EMBASE databases were searched from January 2010 to August 2017. Terms such as Ramadan, Ramadan fasting, diabetes, BMI, body weight, fructosamine, PPG, FPG, *etc*., were used to search appropriate studies in literature.

*Study inclusion/exclusion criteria*: All studies included in the meta-analysis compared the outcomes before and after RF. Studies were included when at least one of the following outcome indicators had been evaluated: PPG, FPG, HbA~1c~ (%), fructosamine levels and BMI. Details are shown in [Figure 1](#F1){ref-type="fig"}. Studies on patients with T2DM with co-morbidities such as cardiovascular disease were excluded. Only studies with adult participants were considered.

![PRISMA flow diagram of search results.](IJMR-150-546-g001){#F1}

*Outcome measures*: In this study, results were combined for five outcome indicators: PPG, FPG, HbA~1c~ (%), fructosamine levels and BMI. Among the included studies, these were the most commonly used outcomes for which results were available.

*Data extraction and quality assessment*: Authors, publication year, sample size, characteristics of the population studied and outcome measures were recorded. Two authors independently screened the titles, abstracts and keywords to identify eligibility and assessed methodological quality of the included studies and recorded the findings and the studies were included when both agreed. Any disagreement was discussed with a third author. Quality of the paper was assessed based on the Newcastle-Ottawa Scale[@ref12]. All of included studies achieved a score of 7 out of 8 on that scale. All of the outcome variables were continuous, and means and standard deviations were used as descriptive statistics.

*Treatment subgroups*: All patients with T2DM participating in the studies included in the meta-analysis were given different therapies. To evaluate the effect of different treatment regimens, studies were classified into three different subgroups: single oral antidiabetics (single OAD), multi-OAD and multitreatment (OAD plus insulin or diet modification).

*Data analysis*: Data analysis was performed using the guideline for statistical methods as described by the Cochrane Collaboration[@ref13]. Random effect models were used to conduct meta-analysis of continuous outcomes to eliminate the effect of heterogeneity on results for all outcomes[@ref14]. A sensitivity analysis was performed to identify studies with poor quality[@ref15]. The earliest, the largest, the smallest and studies with the most contradictory results were excluded sequentially to see how these affected the meta-analysis when included in the sensitivity analysis. Separate funnel plots to assess potential publication bias for individual outcome variables were plotted. Egger regression test[@ref13] to check funnel plot asymmetry was applied using metaphor package in R package v3.5.1 for windows (*<https://cran.r-project.org/bin/windows/base/old/3.5.1/>*). Meta-analysis results were presented with a forest plot. Since the units for the variables differed between the publications, these were converted into the most commonly used units to be able to combine results. The standardized weighted mean difference (SMD) and 95 per cent confidence intervals (CI) were used as a summary statistic in the meta-analysis to assess the same outcome. SMD can be considered as a uniform scale between 0 and 1 to express intervention effect[@ref14][@ref15]. A SMD less than 0.40 is interpreted as a small effect size, a SMD between 0.40 and 0.70 as moderate and \>0.70 as a large effect size[@ref16]. Analysis was performed using RevMan 5.03[@ref17].

Results {#sec1-3}
=======

The search strategy identified a total of 960 records ([Fig. 1](#F1){ref-type="fig"}). Among the 40 studies identified, 19 publications with 33 independent treatment groups met the study inclusion criteria. Details of all included studies and treatments are given in [Table I](#T1){ref-type="table"}. A total sample of 2457 patients was included in the meta-analysis. Five of the included studies were performed in Turkey[@ref18][@ref19][@ref20][@ref21][@ref22], and three were multicentered[@ref23][@ref24][@ref25]. In studies by Almutari[@ref26] and Belkadir[@ref24] younger population was included compared to the rest of the studies. Not all of the study gave gender information, but majority of the studies included both men and women in the study. Duration of fasting varied between 10 and 30 days. Time of measurements for before and after Ramadan was different for each study.

*Effect of Ramadan fasting on PPG*: Ten studies were included[@ref19][@ref20][@ref22][@ref27] in the meta-analysis to estimate the pooled reduction in PPG after RF versus before RF. A total of 199 participants were analyzed, including 108 participants in the monotherapy and 56 participants in the oral combination therapy subgroup. RF had no significant effect in the monotherapy group \[SMD=0.01, 95% CI=(−0.26, 0.28), *P*=0.94\], and no significant difference was observed in the oral combination therapy group \[SMD=0.00, 95% CI=(−0.37, 0.37), *P*=1.000\]. The overall pooled SMD for PPG was 0.06, 95% CI=\[(−) 0.14-0.26\], which was not significant. SMD estimates and their 95 per cent CIs are shown in [Fig. 2](#F2){ref-type="fig"}.

###### 

Summary of the study characteristics included in the meta-analysis

  First author, year                 Country                                             Age range or mean age±SD (yr)   Male/female                 Main outcome                                           Duration of fasting (days)   Time of measurements          Subgroups               Treatments     n                                                                        
  ---------------------------------- --------------------------------------------------- ------------------------------- --------------------------- ------------------------------------------------------ ---------------------------- ----------------------------- ----------------------- -------------- ------------------------------------------------------------------------ -----
  Yeoh *et al*, 2017[@ref33]         Singapore                                           57±11                           15/14                       HbA~1c~ (%), body weight change, blood pressure, TG    \>15                         Before                        Last day                No subgroups   Oral antidiabetic agents alone or insulin therapy + oral antidiabetics   29
  Malha *et al*, 2014[@ref30]        USA                                                 57.0±9.6                        \-                          HbA~1c~ (%), hypoglycaemic events, BMI                 \>15                         Before                        Last day                A              Metformin + vildagliptin                                                 30
  54.6±9.2                           \-                                                  B                               Metformin + sulphonylurea   39                                                                                                                                                                                                                                
  Karatoprak *et al*, 2013[@ref22]   Turkey                                              57.4±10.1                       19/57\*                     HbA~1c~ (%), body weight, BMI, PPG                     29                           15 days                       29^th^ day              A              Insulin premix + metformin                                               12
  B                                  Insulin long-acting + metformin                     13                                                                                                                                                                                                                                                                                            
  C                                  Metformin                                           18                                                                                                                                                                                                                                                                                            
  D                                  Metformin + pioglitazone + acarbose                 17                                                                                                                                                                                                                                                                                            
  Şahin *et al*, 2013[@ref21]        Turkey                                              59.93±9.57                      \-                          PPG, FPG, HbA~1c~ (%), body weight, fructosamine       27                           Two week before               At the end of Ramadan   No subgroup    Glinides + metformin                                                     88
  Almutairi *et al*., 2012[@ref26]   Kuwait                                              28-67                           36/64                       FPG, BMI, CRP, MAP                                     \-                           \-                            \-                      No subgroup    Oral antidiabetics                                                       100
  Vasan *et al*, 2012[@ref27]        India                                               45±9                            \-                          FPG, PPG, body weight, fructosamine, dietary pattern   30                           One week before               One week after          No subgroup    Pioglitazone                                                             50
  Khan *et al*, 2012[@ref34]         Pakistan                                            52.8±8.5                        38/37                       Glucose level, body weight, lipid profile              \>20                         10 days                       seventh day             No subgroup    Oral antidiabetics + insulin                                             75
  Hassanein *et al*, 2011[@ref32]    UK                                                  58.3±13.1                       11/12                       Hypoglycaemic events, HbA~1c~ (%), body weight         \>10                         One-six week                  ≤ six week after        A              Metformin + vildagliptin                                                 23
  57.3±11                            15/21                                               B                               Metformin + suphonylurea    36                                                                                                                                                                                                                                
  Khaled & Belbraouet 2009[@ref25]   Multicenter study/Algeria                           49±6                            0/276                       Anthropometric characteristics and nutrient intakes    \-                           One month before              One month after         No subgroup    Metformin + glimepiride                                                  276
  Devendra *et al*., 2009[@ref35]    UK                                                  53.2±9.7                        18/34                       Body weight, hypoglycaemic event, HbA~1c~              \>15                         Two days before               10 days after           A              Metformin + vildagliptin                                                 26
  B                                  Metformin + gliclazide                              26                                                                                                                                                                                                                                                                                            
  M'guil *et al*, 2008[@ref31]       Morocco                                             48-60                           58/62\*                     BMI, HbA~1c~ (%), fructosamine                         30                           First day                     29^th^ day              No subgroup    Gliclazide                                                               110
  Cesur *et al*, 2007[@ref20]        Turkey                                              56.5±9.2                        29/20                       FPG, PPG, HbA~1c~ (%), fructosamine                    \-                           Two days before               Four days after         A              Glimepiride                                                              21
  B                                  Repaglinide                                         18                                                                                                                                                                                                                                                                                            
  C                                  Glargine                                            10                                                                                                                                                                                                                                                                                            
  Patel *et al*, 2007[@ref36]        Sultanate of Oman                                   54.3±11.7                       146/188                     BMI, sugar intake, food intake, fluid intake           \-                           At the beginning of Ramadan   At the end of Ramadan   No subgroup    Insulin + oral antidiabetics                                             334
  GLIRA study group, 2005[@ref28]    Lebanon                                             53.8±9.2                        123/109                     FPG, HbA~1c~ (%), BMI                                  \-                           One week before               At the end of Ramadan   No subgroup    Glimepiride                                                              232
  Gustaviani *et al*, 2004[@ref29]   Indonesia                                           52.6±8                          10/14                       BMI, FPG, fructosamine                                 \-                           One week before               Two week after          No subgroup    Repaglinide                                                              24
  Sarı *et al*, 2004[@ref19]         Turkey                                              57.79±7                         \-                          BMI, PPG, FPG, HbA~1c~ (%), fructosamine               \-                           \-                            \-                      A              Glimepiride                                                              23
  B                                  Gliclazide                                          17                                                                                                                                                                                                                                                                                            
  Mafauzy, 2002[@ref23]              Multicenter study/Malaysia/UK/France/Saudi Arabia   52.7±7.4                        87/29                       FPG, HbA~1c~ (%), BMI                                  \-                           At the beginning of Ramadan   At the end of Ramadan   A              Repaglinide                                                              116
  54.5±6.9                           82/37                                               B                               Glibenclamide               119                                                                                                                                                                                                                               
  Uysal, 1998[@ref18]                Turkey                                              55                              11/30                       HDL, LDL, HbA~1c~ (%), BMI                             \-                           Two week before               Last week of Ramadan    No subgroup    Diabetic diet or single or combined oral anti-diabetics                  41
  Belkhadir *et al*, 1993[@ref24]    Multicenter study/Morocco                           33-80                           391/198\*                   Fructosamine, HbA~1c~ (%), body weight                 \-                           One day before                One day after           A              Glibenclamide                                                            78
  B                                  Glibenclamide                                       173                                                                                                                                                                                                                                                                                           
  C                                  Glibenclamide                                       95                                                                                                                                                                                                                                                                                            
  D                                  Glibenclamide                                       87                                                                                                                                                                                                                                                                                            
  E                                  Glibenclamide                                       101                                                                                                                                                                                                                                                                                           

\*Mismatch in total number of patients is due to dropout. SD, standard deviation; HbA~1c~, glycated haemoglobin; TG, triglyceride; BMI, body mass index; PPG, post-prandial plasma glucose; FPG, fasting plasma glucose; CRP, C-reactive protein; MAP, mean arterial pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein
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Effect of Ramadan fasting on FPG:Fifteen studies[@ref19][@ref20][@ref22][@ref26][@ref27][@ref28][@ref29][@ref30] reporting estimates for FPG were included. A total of 624 participants were analyzed, including 364 participants in the monotherapy and 135 participants in the insulin combination therapy subgroup. The [Figure 3](#F3){ref-type="fig"} displays the results of the meta-analysis. FPG values were significantly decreased in single OAD \[SMD=0.47, 95% CI=(0.20-0.74), *P*\<0.001\], in the multi-OAD group \[SMD=0.36, 95% CI=(0.11-0.61), *P*=0.005\] as well as in the insulin combination therapy after Ramadan \[SMD=0.65, 95% CI=(0.03-1.27), *P*=0.04\]. Furthermore, the overall result of meta-analysis was significant \[SMD=0.48, 95% CI=(0.27-0.70), *P*\<0.001\]. There was heterogeneity across studies for FPG (*I*[@ref2]=61%, *P*=0.001).
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*Effect of Ramadan fasting on HbA*~1c~: A total of 22 studies[@ref18][@ref19][@ref20][@ref22][@ref24][@ref28][@ref30][@ref31][@ref32][@ref33] provided data for the meta-analysis for HbA~1c~ (%) change (1173 participants, 884 in single OAD, 254 in multi OAD and 35 in multitreatment). In the subgroup analysis, there was no significant difference in monotherapy group \[SMD=0.03, 95% CI=(\[−\]0.23-0.28), *P*=0.84\] and oral combination therapy group \[SMD=0.18, 95% CI=(\[−\]0.29-0.65), *P*=0.45\]. However, in multi-OAD subgroup, small significant reduction was observed \[SMD=0.26, 95% CI=(0.03-0.49), *P*=0.03\]. The overall results of random effects model showed that RF did not lead to significant changes in HbA~1c~ (%) levels \[SMD=0.13, 95% CI=(\[−\]0.04-0.30), *P*=0.13\] ([Fig. 4](#F4){ref-type="fig"}). There was heterogeneity across studies for HbA~1c~ (%) (I[@ref2]=71%, *P*=0.01), but there was no difference between subgroups (*P*=0.72).
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*Effect of Ramadan fasting on fructosamine*: Fifteen studies[@ref19][@ref20][@ref23][@ref24][@ref27][@ref29][@ref31] were included in the meta-analysis to estimate the pooled changes in fructosamine after RF compared to before RF. A total of 998 participants were analyzed to evaluate changes in fructosamine levels. Most of the participants received monotherapy (n=943). RF had no significant effect \[SMD=(−)0.08, 95% CI=(\[−\]0.24, 0.08), *P*=0.320\]. SMD estimates and their 95 per cent CIs are shown in [Fig. 5](#F5){ref-type="fig"}. There was heterogeneity across studies for fructosamine (*I*[@ref2]=65%, *P*=0.001).
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*Effect of Ramadan fasting on body mass index*: Nine[@ref18][@ref26][@ref27][@ref30][@ref31][@ref33][@ref34][@ref35][@ref36] studies representing T2DM population of 959 participants reported BMI scores before and after RF. Overall, meta-analysis results of the random effects model showed marginally significant reduction in BMI levels compared to pre-Ramadan levels as shown in [Fig. 6](#F6){ref-type="fig"} \[SMD=0.09, 95% CI=(\[−\]0.00-0.18), *P*=0.06\]. Furthermore, in the multi-OAD group, there was a significant decrease in BMI values \[SMD=0.18, 95% CI=(0.04-0.31), *P*=0.01\].
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Discussion {#sec1-4}
==========

One major finding of our meta-analysis was the reduction in the HbA~1c~ (%) and FPG in the multi-OAD subgroup after Ramadan. In addition to these glycaemic parameters, BMI values were lower after Ramadan in this subgroup. Another meta-analysis on healthy controls also reported significant decrease in body weight after RF[@ref6]. Body weight reduction might have led to improvement in these glycaemic parameters. Norris *et al*[@ref37] showed that relatively modest weight loss was significantly associated with improvement in FPG and HbA~1c~. Fujioka[@ref38] showed that even the intention to lose weight, without significant success, improved outcomes in patients with diabetes and moderate weight loss had positive effects on metabolic control. However, another meta-analysis examining non-pharmacological weight loss in adults with T2DM did not report significant changes in HbA~1c~[@ref39]. Another meta-analysis which assessed the benefit of low calorie diet programmes in obese patients reported dramatic reductions in FPG values after two weeks and relative improvement in FPG over the course of a single week, when three per cent decrease was achieved in body weight[@ref40]. Overall results of our meta-analysis also showed significant FPG reductions after Ramadan and overall BMI result was marginally significant. We did not find a significant FPG reduction in the single OAD group. Fasting patients consume substantial amounts of sugary foods and carbohydrate-rich meals during non-fasting hours[@ref5]. Therefore, monotherapy alone for the treatment of diabetes may not be sufficient for FPG control.

Since smoking is not permitted during RF, there is a consequential reduction in smoking and tobacco consumption among fasting diabetic patients. Another explanation for the improvement in FPG and HbA~1c~ (%) could be cessation or reduction of smoking during Ramadan. In healthy young males, an increased insulin resistance was observed in acute smokers[@ref41]. Other studies showed that smoking reduced insulin-mediated glucose uptake by 10-40 per cent when compared to non-smokers[@ref42][@ref43]. Other studies showed a positive association between HbA~1c~ and total smoking exposure as measured by pack-years[@ref44][@ref45]. One of the reasons for positive outcomes of our meta-analysis could be increased treatment adherence during Ramadan. It has been shown that in most of the countries, non-adherence rates are surprisingly high during RF[@ref46][@ref47][@ref48]. However, the VIRTUE study enrolling 1333 patients from 10 countries reported high treatment adherence during Ramadan, with low or similar number of missed doses compared to other months[@ref49].

The sensitivity analysis showed similar SMDs for all of the outcomes ([Table II](#T2){ref-type="table"}). For fructosamine, HbA~1c~ (%) and FPG significant heterogeneity were detected among included studies. Not all of the included studies followed the same duration of fasting (Table I). Hence, duration of fasting may be one of the reasons for heterogeneity. Egger regression analysis showed no publication bias for PPG (*P*=0.068), FBG (*P*=0.802), BMI (*P*=0.622) and fructosamine (*P*=0.950). For HbA~1c~ (%), publication bias was detected (*P*=0.015).

###### 

Result of sensitivity analysis

  Outcome        Effect size          Heterogeneity   Sensitivity analysis                                                                  
  -------------- -------------------- --------------- ---------------------- -------------------- -------------------- -------------------- --------------------
  PPG (mg/dl)    0.06 (−0.14-0.26)    0               0.900                  0.13 (−0.10-0.35)    0.03 (−0.17-0.23)    0.05 (−0.17-0.27)    0.09 (−0.11-0.30)
  FPG (mg/dl)    0.48 (0.27-0.70)     61              0.001                  0.44 (0.20-0.69)     0.49 (0.28-0.71)     0.54 (0.32-0.76)     None
  HbA~1C~ (%)    0.13 (−0.04-0.30)    71              0.001                  0.05 (−0.07-0.17)    0.13 (−0.04-0.30)    0.14 (−0.03-0.32)    0.16 (−0.01-0.32)
  BMI            0.09 (−0.00-0.18)    0               0.810                  0.04 (−0.07-0.14)    0.08 (−0.01-0.18)    0.09 (−0.00-0.18)    0.04 (−0.07-0.14)
  Fructosamine   −0.08 (−0.24-0.08)   65              0.001                  −0.09 (−0.27-0.09)   −0.08 (−0.25-0.09)   −0.03 (−0.27-0.22)   −0.05 (−0.21-0.11)

HbA~1c~, glycated haemoglobin; TG, triglyceride; BMI, body mass index; PPG, post-prandial plasma glucose; FPG, fasting plasma glucose

Our study had several limitations. Although studies with co-morbidities were excluded, it was very difficult to include only those cases of diabetes without co-morbid conditions, and most of the studies did not follow similar inclusion criteria. The reported rates of hypoglycaemic and hyperglycaemic and hyperglycaemic rate events vary between 3.7 and 33.3 per cent[@ref18][@ref19][@ref22]. Since only a small number of studies reported these outcomes, we could not include them in our meta-analysis. Another limitation of our study was related to the fact that most of the included studies investigated the impact of RF just after Ramadan; therefore, sustainability of positive outcomes could not be evaluated.

In conclusion, our meta-analysis showed that RF was not associated with any significant negative effects on PPG and fructosamine levels. However, BMI and FPG and HbA~1c~ (%) were positively affected by RF. Although RF showed positive effects on certain outcomes, one should consider the limitations of the study and confounders while interpreting the results.
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